12/10/2025
🚨 Dupixent Alert 🚨
Dupixent (dupilumab) has been linked to development or worsening of CTCL (Cutaneous T-cell Lymphoma), a rare type of non-Hodgkin lymphoma where cancerous T-cells (a type of white blood cell) primarily attack the skin, causing itchy, scaly patches, red or discolored skin, and sometimes lumps.
Read more: https://lfsblaw.com/dupixent-lawsuit/
If you have been diagnosed with CTCL after taking Dupixent, you may be entitled to compensation. Contact us today for a free case evaluation.